If you are looking for innovation-friendly corporations, AstraZeneca should be at the very top of your list. This biopharmaceutical company delivers new medicines to millions of patients while encouraging scientists, researchers, and entrepreneurs to work on the pressing issues of contemporary medicine. It is one of the leaders in the international biopharmaceutical market and a partner of the impact ‘17 conference.
During the last few months, AstraZeneca has flooded Poland with investments. Back in March, the company decided to expand their global R&D hub located in Warsaw. Just a couple days later, they announced that they chose Warsaw as the location for one of the three global financial and HR centers. These investments make Poland one of the key countries for AstraZeneca’s operations. Soon Poland will be home to more than 1100 AstraZeneca employees.
“Expanding the company’s high level clinical & research activities is the very beginning of my dream of Poland becoming a global biotechnology center,” said Jarosław Oleszczuk, the Country President of AstraZeneca Pharma Poland. “In 10-15 years, Poland can become a biotech hub comparable to Boston, Silicon Valley, Belgium, or Switzerland. I hope to see hundreds of biotechnological companies operating in our country and developing breakthrough treatments.”
Poland has a great potential to become a key player in the field of life sciences. Poland’s pharmaceutical market is the sixth biggest in Europe and develops dynamically. Oleszczuk admits that even though a lot of research projects are going on in Poland, scientists often don’t commercialize their results. AstraZeneca tries to reverse this trend by encouraging researchers and startups to work on new innovative medicines. “The field of biotechnology is on the verge of multiple global revolutions. Only the players brave enough to engage in disruptive thought will stay in the game,” Oleszczuk added.
One of the global initiatives of AstraZeneca, called Open Innovation, is a database of 250 thousand preclinical and clinical projects that have never been finished yet. This database is publicly accessible to researchers from all across the globe. Scientists, who have an idea how to develop one of these projects, can count on the support of AstraZeneca in the form of a joint venture. Oleszczuk emphasized that he counts on a greater interest in this project among young scientists in Poland.
AstraZeneca in Poland conducts clinical research in 500 various centers, giving 7500 Polish patients access to the most modern treatments. The company also strives to reduce the bureaucratic obstacles in registering new medications and plans to introduce globally 15-20 new medications over the next five years.
AstraZeneca is impact’17 Partner.
Visit AstraZeneca website: https://www.astrazeneca.pl
AstraZeneca project Open Innovation: https://openinnovation.astrazeneca.com/
